• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    7/10/26 11:43:15 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIXT alert in real time by email
    false 0001335105 0001335105 2026-07-08 2026-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): July 8, 2026

     

    NOMAD POWER SOLUTIONS, INC.

    (Exact name of registrant as specified in its charter)

     

    delaware   001-39717   20-2903526

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

     

    433 Plaza Real, Suite 275

    Boca Raton, Florida 33432

    (Address of principal executive offices)

     

    (631) 830-7092

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   NMAD   The NASDAQ Stock Market, LLC

     

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 7.01 Regulation FD Disclosure

     

    On July 8, 2026, Nomad Power Solutions, Inc., (the “Company”), issued a press release announcing the capacity increase of its fleet-wide energy storage. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

     

    The information in this Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

     

    Item 9.01 Financial Statements and Exhibits

     

    (d) Exhibits. The following exhibits are filed herewith.

     

    Exhibit

    Number

      Description
    99.1   Pree Release dated July 8, 2026
    104   Cover Page Interactive Data File (embedded within the inline XBRL Document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: July 10, 2026 NOMAD POWER SOLUTIONS, INC.
      (Registrant)
         
      By:  /s/ Geordan Pursglove
        Geordan Pursglove
        Chairman of the Board and Chief Executive Officer

     

     

     

    Get the next $LIXT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIXT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LIXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Stazzone Peter was granted 50,000 shares, increasing direct ownership by 100% to 100,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    7/2/26 4:18:44 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sawyer Jason David was granted 40,000 shares, increasing direct ownership by 160% to 65,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    7/2/26 4:16:48 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman of the Board Pursglove Geordan Garrett was granted 350,000 shares, increasing direct ownership by 100% to 700,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    7/2/26 4:13:51 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 67% to 25,000 units (SEC Form 4) (Amendment)

    4/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/5/23 8:39:03 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Van Der Baan Bastiaan Jeroen bought $28,000 worth of shares (10,000 units at $2.80), increasing direct ownership by 1,000% to 11,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/5/23 8:36:30 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 33% to 20,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/4/23 6:10:01 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    SEC Filings

    View All

    SEC Form PRE 14A filed by Lixte Biotechnology Holdings Inc.

    PRE 14A - NOMAD POWER SOLUTIONS, INC. (0001335105) (Filer)

    7/17/26 5:29:27 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NOMAD POWER SOLUTIONS, INC. (0001335105) (Filer)

    7/10/26 11:43:15 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    7/2/26 4:00:46 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD

    Issued on behalf of NOMAD Power Solutions, Inc. (NASDAQ:NMAD), formerly LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT)NOMAD Power Solutions, Inc. has completed its corporate name change from LIXTE Biotechnology Holdings, Inc. and begins trading today under the new Nasdaq ticker NMAD, marking its transition into the AI energy infrastructure equipment and services sector following its acquisition of NOMAD Transportable Power SystemsAmerican News Group News CommentaryBOCA RATON, Fla., July 6, 2026 /CNW/ -- The artificial intelligence buildout has run headlong into a physical bottleneck: electricity. Data centers are demanding power faster than the grid can add it through traditional fixed inf

    7/6/26 11:40:00 AM ET
    $FLNC
    $BE
    $GEV
    Industrial Machinery/Components
    Miscellaneous
    Energy
    Biotechnology: Pharmaceutical Preparations

    LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD

     -- New Corporate Identity Reflects Strategic Transition into AI Energy Infrastructure Equipment & Services Sector Following Acquisition of NOMAD Transportable Power Systems -- BOCA RATON, Fla., July 06, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. ("NOMAD" or the "Company"), today announced that it has completed its name change from LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) to NOMAD Power Solutions, Inc (NASDAQ:NMAD). The Company’s common stock will begin trading today under its new ticker, NMAD on the Nasdaq Stock Market. Shares under the symbol LIXT ceased trading at the close of market on Thursday, July 2, 2026. The new corporate name reflects the next chapter for the

    7/6/26 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS

    -Transaction Transforms LIXTE to New Growth Sector Addressing Multi-Billion-Dollar Market of Mobile, Utility-Grade Battery Energy Storage Systems-                                          -Company Plans Corporate Name Change to NOMAD Power Solutions                                       BOCA RATON, Fla./WATERBURY, Vt., July 02, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company") today announced it has completed the previously announced merger with NOMAD Transportable Power Systems, Inc. ("NOMAD"), a market leader in deployable, utility-grade battery energy storage systems (BESS), In connection with the merger, the Company is issuing to the

    7/2/26 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Leadership Updates

    Live Leadership Updates

    View All

    LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors

    Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE's Strategic Expansion into AI Energy Infrastructure BOCA RATON, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), today announced its strategic transformation into an AI energy infrastructure equipment & services platform focused on meeting the rapidly growing power demands of AI and hyperscale data centers. In connection with this transformation, Stuart D. Porter, Founder, Managing Partner, Chief Executive Officer and Chief Investment Officer of Denham Capital Managemen

    6/1/26 8:50:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his

    2/18/26 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

    -- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced that Lourdes Felix and Guy Primus have joined the Company's Board of Directors, and Peter Stazzone has been named Chief Financial Officer. The Company also announced that it has relocated its corporate headquarters to Boca Raton. The new board members succeed Bas van der Baan, who remains Chief Scientific Officer of LIXTE, and René Bernards, PhD, who has been n

    9/3/25 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Financials

    Live finance-specific insights

    View All

    LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

    BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report is available on the Company's website, www.lixte.com, and on the SEC's website, www.sec.gov. "2025 was a transformative and highly productive year for our Company," said Geordan Pursglove, who was named LIXTE's Chairman and Chief Executive Officer in June 2025. "We strengthened LIXTE's foundation by assembling an

    3/31/26 3:45:00 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

    Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe Ltd., a UK-based company pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora will become a wholly owned subsidiary of LIXTE. The acquisition includes Liora's proprietary flagship technology LiGHT Sys

    11/25/25 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Lixte Biotechnology Holdings Inc.

    SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    4/6/22 9:58:22 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lixte Biotechnology Holdings Inc. (Amendment)

    SC 13G/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    4/6/22 9:59:12 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed

    SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    3/3/21 7:45:27 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care